Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30367101 | 0.75 | MAPK1 (0.35) | TAAR1SLC6A2MEN1ALDH1A1GAA | |
| SCHEMBL3415811 | 0.73 | — | — | |
| SCHEMBL18398 | 0.72 | MAPK1 (0.36) | TAAR1SLC6A2MEN1ALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL1295227 | 0.70 | MAPK1 (0.35) | TAAR1SLC6A2MEN1ALDH1A1GAA | |
| SCHEMBL5613562 | 0.69 | MAPK1 (0.33) | TAAR1SLC6A2ALDH1A1TSHRLMNA | |
| SCHEMBL12814594 | 0.68 | TAAR1 (0.32) | TAAR1SLC6A2TRPA1MEN1ALDH1A1 | |
| SCHEMBL9123089 | 0.67 | TAAR1 (0.33) | TAAR1MAPK1 | |
| SCHEMBL10318688 | 0.65 | RIPK1 (0.34) | TAAR1SLC6A2TRPA1 | |
| SCHEMBL27602393 | 0.65 | ALDH1A1 (0.32) | TAAR1SLC6A2MEN1ALDH1A1GAA | |
| SCHEMBL9746363 | 0.65 | TAAR1 (0.30) | TAAR1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373932-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-23 | — | — | US | disclosed |
| EP-3447045-B9 | 1-(1-HYDROXY-2,3-DIHYDRO-1H-INDEN-5-YL)-UREA DERIVATIVES AND RELATED COMPOUNDS KCNQ 2-5 CHANNEL ACTIVATORS FOR TREATING DYSURIA | ONO PHARMACEUTICAL CO (JP) | 2021-07-21 | — | — | EP | disclosed |
| US-20210130300-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2021-05-06 | — | — | US | disclosed |
| EP-3210969-B1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO (JP) | 2021-04-28 | — | — | EP | disclosed |
| EP-3447045-B1 | 1-(1-HYDROXY-2,3-DIHYDRO-1H-INDEN-5-YL)-UREA DERIVATIVES AND RELATED COMPOUNDS KCNQ 2-5 CHANNEL ACTIVATORS FOR TREATING DYSURIA | ONO PHARMACEUTICAL CO (JP) | 2021-03-03 | — | — | EP | disclosed |
| EP-3744713-A1 | DIYHYDROPYRIMIDINE-2-ONE COMPOUNDS AND MEDICINAL USES THEREOF | Japan Tobacco Inc. (JP) | 2020-12-02 | — | — | EP | disclosed |
| CN-107108485-B | KCNQ 2-5 channel activator | 小野药品工业株式会社 | 2020-06-12 | — | — | CN | disclosed |
| US-10676438-B2 | KCNQ2-5 channel activator | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-09 | — | — | US | disclosed |
| US-20200157050-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
| CN-107573498-B | Polyoxyethylene derivative having plural hydroxyl groups at terminal | 日油株式会社 | 2020-04-24 | — | — | CN | disclosed |
| US-6130222-A | Compounds with analgesic effect | ASTRA PHARMA INC. (CA) | 2000-10-10 | — | — | US | disclosed |
| EP-0739349-B1 | POLYMER-SUPPORTED SOLUTION SYNTHESIS OF OLIGOSACCHARIDES | INNOVATIONS FOUNDATION (CA) | 2000-05-17 | — | — | EP | disclosed |
| EP-0915855-A1 | NOVEL COMPOUNDS WITH ANALGESIC EFFECT | Astra Pharma Inc. (CA) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998048786-A1 | AMINOTETRALINS AS 5-HT1Dα AGONISTS | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| US-5616698-A | Polymer-supported solution synthesis of oligosaccharides | UNIVERSITY OF TORONTO INNOVATIONS FOUNDATION (CA) | 1997-04-01 | — | — | US | disclosed |
| EP-0739349-A1 | POLYMER-SUPPORTED SOLUTION SYNTHESIS OF OLIGOSACCHARIDES | INNOVATIONS FOUNDATION (CA) | 1996-10-30 | — | — | EP | disclosed |
| WO-1995018814-A2 | POLYMER-SUPPORTED SOLUTION SYNTHESIS OF OLIGOSACCHARIDES | INNOVATIONS FOUNDATION (CA) | 1995-07-13 | — | — | WO | disclosed |
| US-5175267-A | Stereoselective glycosylation of hetercyclic bases | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1992-12-29 | — | — | US | disclosed |
| US-5006511-A | Treating hypertension, congestive heart failure | MERCK & CO., INC. (US) | 1991-04-09 | — | — | US | disclosed |
| EP-0312283-A2 | Di-or tripeptide renin inhibitors containing lactam conformational restrictions in ACHPA | MERCK & CO. INC. (US) | 1989-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157050-A1 | KCNQ2-5 CHANNEL ACTIVATOR | KCNQ5, KCNQ2, KCNQ1 | TAAR1 2082/4885SLC6A2 1294/4885TRPA1 103/4885 |
| US-20210130300-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | REN, PKD2, ALPI | TAAR1 3206/4885SLC6A2 134/4885TRPA1 405/4885 |
| US-20230373932-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | REN, PKD2, ALPI | TAAR1 3206/4885SLC6A2 134/4885TRPA1 405/4885 |
| US-10676438-B2 | KCNQ2-5 channel activator | KCNQ5, KCNQ2, KCNQ1 | TAAR1 2082/4885SLC6A2 1294/4885TRPA1 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.